COVID-19 vaccine hesitancy in underserved communities of North Carolina.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
03
2021
accepted:
21
07
2021
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
16
11
2021
Statut:
epublish
Résumé
In the United States, underserved communities including Blacks and Latinx are disproportionately affected by COVID-19. This study sought to estimate the prevalence of COVID-19 vaccine hesitancy, describe attitudes related to vaccination, and identify correlates among historically marginalized populations across 9 counties in North Carolina. We conducted a cross-sectional survey distributed at free COVID-19 testing events in underserved rural and urban communities from August 27 -December 15, 2020. Vaccine hesitancy was defined as the response of "no" or "don't know/not sure" to whether the participant would get the COVID-19 vaccine as soon as it became available. The sample comprised 948 participants including 27.7% Whites, 59.6% Blacks, 12.7% Latinx, and 63% female. 32% earned <$20K annually, 60% owned a computer and ~80% had internet access at home. The prevalence of vaccine hesitancy was 68.9% including 62.7%, 74%, and 59.5% among Whites, Blacks, and Latinx, respectively. Between September and December, the largest decline in vaccine hesitancy occurred among Whites (27.5 percentage points), followed by Latinx (17.6) and only 12.0 points among Blacks. 51.2% of respondents reported vaccine safety concerns, 23.7% wanted others to get vaccinated first, and 63.1% would trust health care providers about the COVID-19 vaccine. Factors associated with hesitancy in multivariable logistic regression included being female (OR = 1.90 95%CI [1.36, 2.64]), being Black (OR = 1.68 1.16, 2.45]), calendar month (OR = 0.76 [0.63, 0.92]), safety concerns (OR = 4.28 [3.06, 5.97]), and government distrust (OR = 3.57 [2.26, 5.63]). This study engaged the community to directly reach underserved minority populations at highest risk of COVID-19 that permitted assessment of vaccine hesitancy (which was much higher than national estimates), driven in part by distrust, and safety concerns.
Sections du résumé
BACKGROUND
In the United States, underserved communities including Blacks and Latinx are disproportionately affected by COVID-19. This study sought to estimate the prevalence of COVID-19 vaccine hesitancy, describe attitudes related to vaccination, and identify correlates among historically marginalized populations across 9 counties in North Carolina.
METHODS
We conducted a cross-sectional survey distributed at free COVID-19 testing events in underserved rural and urban communities from August 27 -December 15, 2020. Vaccine hesitancy was defined as the response of "no" or "don't know/not sure" to whether the participant would get the COVID-19 vaccine as soon as it became available.
RESULTS
The sample comprised 948 participants including 27.7% Whites, 59.6% Blacks, 12.7% Latinx, and 63% female. 32% earned <$20K annually, 60% owned a computer and ~80% had internet access at home. The prevalence of vaccine hesitancy was 68.9% including 62.7%, 74%, and 59.5% among Whites, Blacks, and Latinx, respectively. Between September and December, the largest decline in vaccine hesitancy occurred among Whites (27.5 percentage points), followed by Latinx (17.6) and only 12.0 points among Blacks. 51.2% of respondents reported vaccine safety concerns, 23.7% wanted others to get vaccinated first, and 63.1% would trust health care providers about the COVID-19 vaccine. Factors associated with hesitancy in multivariable logistic regression included being female (OR = 1.90 95%CI [1.36, 2.64]), being Black (OR = 1.68 1.16, 2.45]), calendar month (OR = 0.76 [0.63, 0.92]), safety concerns (OR = 4.28 [3.06, 5.97]), and government distrust (OR = 3.57 [2.26, 5.63]).
CONCLUSIONS
This study engaged the community to directly reach underserved minority populations at highest risk of COVID-19 that permitted assessment of vaccine hesitancy (which was much higher than national estimates), driven in part by distrust, and safety concerns.
Identifiants
pubmed: 34723973
doi: 10.1371/journal.pone.0248542
pii: PONE-D-21-07150
pmc: PMC8559933
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0248542Subventions
Organisme : NIMHD NIH HHS
ID : R01 MD012767
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD012392
Pays : United States
Commentaires et corrections
Type : UpdateOf
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Infect Dis. 2011 Apr 1;52(7):911-6
pubmed: 21427399
Vaccines (Basel). 2021 Feb 03;9(2):
pubmed: 33546165
Health Commun. 2020 Dec;35(14):1707-1710
pubmed: 33081500
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1657-1660
pubmed: 33382671
J Relig Health. 2012 Mar;51(1):148-60
pubmed: 19960262
Soc Sci Med. 2021 Jan;268:113554
pubmed: 33308911
Ann Intern Med. 2020 Dec 15;173(12):964-973
pubmed: 32886525
Vaccine. 2020 Sep 29;38(42):6500-6507
pubmed: 32863069
Vaccines (Basel). 2020 Oct 03;8(4):
pubmed: 33022917
Vaccine. 2021 Feb 12;39(7):1080-1086
pubmed: 33461833
J Infect Dis. 2010 Jun 1;201(11):1607-10
pubmed: 20402594
J Natl Med Assoc. 2010 Sep;102(9):823-31
pubmed: 20922927
J Infect. 2020 Jun;80(6):e32-e33
pubmed: 32209383
Front Psychol. 2020 Oct 19;11:575950
pubmed: 33192883
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Vaccine. 2021 Jan 29;39(5):825-829
pubmed: 33390295
J Community Health. 2021 Apr;46(2):270-277
pubmed: 33389421
JAMA. 2020 Dec 29;:
pubmed: 33372943
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
JAMA. 2021 Jan 12;325(2):123-124
pubmed: 33331845
Soc Sci Med. 2021 Mar;272:113638
pubmed: 33414032
JAMA. 2020 Oct 20;324(15):1562-1564
pubmed: 33044483
JAMA Netw Open. 2020 Oct 1;3(10):e2025594
pubmed: 33079199
medRxiv. 2020 Nov 30;:
pubmed: 33269354
JAMA. 2020 Jun 23;323(24):2466-2467
pubmed: 32391864
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 Feb 18;384(7):e23
pubmed: 33406324